DadFinStart your free week
DadFin › Stocks › Healthcare › MDWD

MediWound Ltd. (MDWD) stock score

Healthcare · Biotechnology · Israel

$13.55 ▲ +5.04% today

17.2
Dad Score, out of 100
weak

MediWound Ltd. (MDWD) is a Biotechnology company in the Healthcare sector, listed in Israel. On DadFin's weekly run it scores 17.2 out of 100 on the Dad Score, a weak reading that places the business ahead of 17% of the 5,684 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #762 of 956. Its strongest axis is risk; its weakest are valuation and growth.

Scores from the run of Nov 15, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Average
Growth
Weak
Price action
Average
Risk
Above average
Conviction
Below average
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)-5.7×
Dividend yield0.00%
Return on capital-38.5%
Operating margin-337.6%
Revenue growth (YoY)-16.1%
FCF yield-12.0%
Net debt / EBITDA3.00×
Piotroski F-Score4 / 9
52-week change-29.8%
Market cap$186M
Next earningsMar 4, 2027

What subscribers see on MDWD

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate75.0good$136.6B
REGNRegeneron Pharmaceuticals, Inc.98.6strong$98.8B
MRNAModerna, Inc.31.8weak$90.4B
ARGXargenx SE86.7strong$60.4B
ONCBeOne Medicines AG95.0strong$47.6B
RPRXRoyalty Pharma plc98.2strong$39.9B
RVMDRevolution Medicines, Inc.44.8middling$37.3B
GMABGenmab A/S63.2middling$31.7B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 15, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.